Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
about
Contemporary use of bevacizumab in ovarian cancerEffect of indirect nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro and in vivo.Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model.Effects of Treg cells and IDO on human epithelial ovarian cancer cells under hypoxic conditionsCombination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer modelIn vivo monitoring of angiogenesis inhibition via down-regulation of mir-21 in a VEGFR2-luc murine breast cancer model using bioluminescent imaging.A network model for angiogenesis in ovarian cancer.EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinomaAngiogenesis-related pathways in the pathogenesis of ovarian cancerSynthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy.Epithelial ovarian cancer-induced angiogenic phenotype of human omental microvascular endothelial cells may occur independently of VEGF signaling.The Notch ligand Delta-like 4 (DLL4) as a target in angiogenesis-based cancer therapy?The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.Photoacoustic Tomography Detects Early Vessel Regression and Normalization During Ovarian Tumor Response to the Antiangiogenic Therapy Trebananib.Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation.VSV based virotherapy in ovarian cancer: the past, the present and …future?
P2860
Q27023510-C9D39A4F-125F-43C5-8F85-0C27D07C598EQ33460375-7DC2297D-5AF2-43D4-B223-78E55D559291Q34092176-5C8D2498-22E7-4D77-AD44-2FF6990E91CCQ34731353-4882DC87-8CC6-4BD5-9950-F6711304BF0CQ34849516-78C331B5-1989-49C0-87DB-742D1E6C4470Q34949654-0CB21FF7-D370-4169-8AEC-BC4F1BDA01BBQ35534413-941DBC79-62E2-47AC-9E9C-7A06824492E2Q35829712-EB9E3966-21E0-461A-9239-FBBC13859C7BQ36103829-7B5073EE-FBED-4A7A-8B70-9723B12F18F7Q37139109-DC94825F-AF9C-431C-990B-A05A029B08CBQ37260459-66FB609F-6B15-478D-9B19-0FDB5E2F844CQ37474379-4844C5BF-64A1-4F53-A5D4-20D09D390C74Q37601970-8D78D1B3-839B-4D80-92B8-860F17BC75BBQ38751138-376204AB-326C-4533-A905-7F715FB49A4EQ38757677-4CE9D319-AA6D-4C80-BD94-C2B90A23A368Q38840159-D7BE2469-1E7C-4E8A-9701-6F5A1A8788D2Q39239168-F28E2C36-44A1-4B1A-B5EE-6334EE3B4307Q41441101-1ABD5138-7352-4814-B173-D45B227D1A4D
P2860
Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antiangiogenic agents in combi ...... of epithelial ovarian cancer.
@en
Antiangiogenic agents in combi ...... of epithelial ovarian cancer.
@nl
type
label
Antiangiogenic agents in combi ...... of epithelial ovarian cancer.
@en
Antiangiogenic agents in combi ...... of epithelial ovarian cancer.
@nl
prefLabel
Antiangiogenic agents in combi ...... of epithelial ovarian cancer.
@en
Antiangiogenic agents in combi ...... of epithelial ovarian cancer.
@nl
P1476
Antiangiogenic agents in combi ...... of epithelial ovarian cancer.
@en
P2093
Deanna Teoh
P304
P356
10.1097/IGC.0B013E31823C6EFD
P577
2012-03-01T00:00:00Z